Simon E. Koele

Simon E. Koele

Auto-generated profile, based on publicly available information

Simon E. Koele

Department of Pharmacy, Pharmacology, and Toxicology, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2023 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
SKSimon E. Koele
Simon E. Koele
PPPatrick P.J. Phillips
Patrick P.J. Phillips
CUCaryn M. Upton
Caryn M. Upton
JIJakko van Ingen
Jakko van Ingen
Ulrika SH SimonssonUlrika SH Simonsson
Ulrika SH Simonsson
ESElin M. Svensson
Elin M. Svensson
A milestone in the development of novel antituberculosis drugs is the demonstration of early bactericidal activity (EBA) in a phase IIa clinical trial. The significant variability in measurements of bacterial load complicates data analysis in these trials. A systematic review and evaluation of methods for determination of EBA in pulmonary tuberculosis studies was undertaken. Bacterial load quantification biomarkers, reporting intervals, calculation methods, statistical testing, and handling of negative culture results were extracted. In total, 79 studies were identi-fied in which EBA was determined. Colony-forming units on solid culture media and/or time-to-positivity in liquid media were the biomarkers used most often, reported in 72 (91%) and 34 (43%) studies, respec-tively. Twenty-two different reporting intervals were presented, and 12 different calculation methods for EBA were identified. Statistical testing for a significant EBA compared with no change was performed in 54 (68%) studies, and between-group testing was performed in 32 (41%) studies. Negative culture result handling was discussed in 34 (43%) studies. Notable variation was found in the analysis methods and reporting of EBA studies. A standardized and clearly reported analysis method, accounting for different levels of variability in the data, could aid the generalization of study results and facilitate comparison between drugs/regimens. (c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )

8 October 2024 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
RSRalf Stemkens
Ralf Stemkens
ALArthur Lemson
Arthur Lemson
SKSimon E Koele
Simon E Koele
ESElin M Svensson
Elin M Svensson
LBLindsey H M Te Brake
Lindsey H M Te Brake
RARob E Aarnoutse
Rob E Aarnoutse
Objectives: Clofazimine is a promising drug for the treatment of nontuberculous mycobacterial (NTM) diseases. Accumulation of clofazimine to reach steady-state plasma concentrations takes months. A loading dose may reduce the time to steady-state-like concentrations. We evaluated the pharmacokinetics (PK), safety and tolerability of a loading dose regimen in patients with NTM disease. Methods: Adult participants received a 4-week loading dose regimen of 300 mg clofazimine once daily, followed by a maintenance dose of 100 mg once daily (combined with other antimycobacterial drugs). Blood samples for PK analysis were collected on three occasions. A population PK model for clofazimine was developed and simulations were performed to assess the time to reach steady-state-like (target) concentrations for different dosing regimens. Results: Twelve participants were included. The geometric mean peak and trough clofazimine concentrations after the 4-week loading phase were 0.87 and 0.50 mg/L, respectively. Adverse events were common, but mostly mild and none led to discontinuation of clofazimine. Our loading dose regimen reduced the predicted median time to target concentrations by 1.5 months compared to no loading dose (3.8 versus 5.3 months). Further time benefit was predicted with a 6-week loading dose regimen (1.4 versus 5.3 months). Conclusion: A 4-week loading dose regimen of 300 mg once daily reduced the time to target clofazimine concentrations and was safe and well-tolerated. Extending the loading phase to 6 weeks could further decrease the time to target concentrations. Using a loading dose of clofazimine is a feasible strategy to optimize treatment of NTM disease. Clinical Trials Registration: NCT05294146

28 March 2025 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
SKSimon E Koele
Simon E Koele
NHNorbert Heinrich
Norbert Heinrich
VJVeronique R De Jager
Veronique R De Jager
JDJulia Dreisbach
Julia Dreisbach
PPPatrick P J Phillips
Patrick P J Phillips
ESElin M Svensson
Elin M Svensson
Introduction: BTZ-043 is a first-in-class benzothiazinone for the treatment of TB with demonstrated early bactericidal activity. BTZ-043 is metabolized into two major metabolites: M1 and M2. The aim of this study was to characterize the pharmacokinetics (PK) and early exposure–response (pharmacokinetic/pharmacodynamic, PK/PD) relationship for BTZ-043. Methods: A population PK/PD model for BTZ-043 and its metabolites was developed using data from a sequential Phase 1b/2a, randomized, controlled clinical trial in participants with pulmonary TB. BTZ-043 was administered in daily doses ranging from 250 to 1750 mg over 14 days. The decrease in bacterial load was determined by culture of sputum samples to quantify cfu on solid medium, and time to positivity in liquid medium. Results: In total, 77 participants received the experimental treatment. PK were best described by two-compartment disposition models for BTZ-043 and M2, and a one-compartment disposition model for M1. When given without food, the bioavailability was 54% (95% CI: 43%–65%) lower than with food. The decrease in bacterial load was described by a bilinear model with estimated node at 48 h. Participants in the highest dose group in Stage 2 (1000 mg) had a 2-fold faster decrease in mycobacterial load during the initial 2 days compared with participants in the lowest dose group (250 mg), driven by an Emax relationship to the BTZ-043total exposure (BTZ-043 + M2). Conclusions: We characterized the population PK/PD of BTZ-043 in trial participants with pulmonary TB. An exposure–response relationship was only apparent for the first 2 days on treatment, indicating the need for further dose-finding studies.

4 July 2025 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
SKSimon E Koele
Simon E Koele
KSKrista Stoycheva
Krista Stoycheva
CMCyprian Mtweve
Cyprian Mtweve
CMChristina Manyama
Christina Manyama
SMStellah Mpagama
Stellah Mpagama
PCPanACEA consortium
PanACEA consortium
Introduction: Many drugs for the treatment of TB prolong the QTc interval, which is associated with an increased risk of developing a life-threatening arrhythmia known as torsades de pointes. Sutezolid and delpazolid are novel oxazolidinones with demonstrated bactericidal activity. We aimed to assess the effects of sutezolid or delpazolid co-administered with bedaquiline, delamanid and moxifloxacin on the QTcF interval (Fridericia’s correction). Furthermore, we developed a population pharmacodynamic model to assess the effects of drug exposure on the QTcTBT interval (TB-specific correction). Methods: Participants were randomized to receive standard-dose bedaquiline, delamanid and moxifloxacin with varying doses of either sutezolid (no sutezolid, 600 mg daily, 1200 mg daily, 600 mg twice daily, 800 mg twice daily) or delpazolid (no delpazolid, 400 mg daily, 800 mg daily, 1200 mg daily, 800 mg twice daily). The QTc interval was determined using weekly ECG assessments. Results: Data from 149 participants, yielding 2373 ECG observations were available for analysis. Nine participants (6.0%) experienced a Grade 3 QTcF prolongation as defined by the Common Terminology Criteria for Adverse Events v5.0. The population pharmacodynamic model predicted a 13.2 ms (95% CI: 10.9–15.3) increase of the QTcTBT in the first week of treatment, but no further increase after that. The exposure of bedaquiline’s M2 metabolite was found to drive part of the QTcTBT. No exposure–response relationship was identified for the other drugs investigated. Conclusions: The drug regimens containing standard doses of bedaquiline, delamanid and moxifloxacin, and varying doses of sutezolid or delpazolid were not found to pose a high cardiac risk in a population without further QTc-relevant risk factors. However, close monitoring of the QTc interval remains essential in patients with TB treated with combination drug therapy with known QTc-prolonging drugs.

7 October 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SKSimon E. Koele
Simon E. Koele
SBStijn W. Beek
Stijn W. Beek
AWAnthonie J. Wekken
Anthonie J. Wekken
BPBerber Piet
Berber Piet
MHMichel M. van Den Heuvel
Michel M. van Den Heuvel
RHRob Heine
Rob Heine
Brigatinib was recently approved for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer and is dosed according to a one-dose-fits-all paradigm. We aimed to identify a pharmacokinetically-guided precision dosing strategy to improve treatment response with brigatinib through simulations using a previously published pharmacokinetic-pharmacodynamic model. Dosing strategies explored were the approved 180mg QD, the highest tolerable dose tested in clinical trials: 240mg QD, and two precision dosing strategies targeting the median trough concentrations following 180mg QD, and 240mg QD. We investigated the impact of alternative dosing regimens on progression-free survival (PFS), overall survival (OS), and the probability of developing a grade ≥2 rash or grade ≥2 amylase increase. Median PFS and OS increased by 1.6 and 7.8 months, respectively between the currently approved dosing strategy and precision dosing to the median trough concentration of the 240mg dosing strategy, with only a minor increase in the probability of developing toxicity.

15 March 2022 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
SKSimon E. Koele
Simon E. Koele
SBStijn W. van Beek
Stijn W. van Beek
GMGary Maartens
Gary Maartens
JBJames C. M. Brust
James C. M. Brust
ESElin M. Svensson
Elin M. Svensson
Interruption of treatment is common in drug-resistant tuberculosis patients. Bedaquiline has a long terminal half-life; therefore, restarting after an interruption without a loading dose could increase the risk of suboptimal treatment outcome and resistance development.